1609100-30-2

Upstream product

• 22031-52-3 2-aza-3-oxobicyclo<3.2.0>heptane 
• 64-17-5 ethanol 
• 38052-23-2 ethyl cis-2-amino-1-cyclopentane-carboxylate 
• 1609100-30-2 ethyl cis-2-aminocyclopentane-1-carboxylate 
• 1346004-19-0 (S,E)-ethyl 6-((1-(4-methoxyphenyl)ethyl)imino)hexanoate 
• 1346004-53-2 (1R,5S)-6-((S)-1-(4-methoxyphenyl)ethyl)-6-azabicyclo[3.2.0]heptan-7-one 
• 39155-94-7 (1R,5S)-6-azabicyclo[3.2.0]heptan-7-one 
• 5299-60-5 6-hydroxy-hexanoic acid ethyl ester 
• 27983-42-2 5-carboethoxypentanal 
• 197916-36-2 ethyl (1R,2S)-2-aminocyclopentane-1-carboxylate 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 1140972-24-2 C₈H₈O₃*C₁₅H₂₀FNO₂ 
• 158262-07-8 cis-ethyl 2-(benzylamino)cyclopentanecarboxylate 
• 61586-79-6 ethyl (1R,2S)-2-hydroxycyclopentanecarboxylate 

Downstream Products

• 197916-36-2 ethyl (1R,2S)-2-aminocyclopentane-1-carboxylate 
• 135053-11-1 cis-2-amino-1-cyclopentanecarboxamide 
• 135053-11-1 trans-2-aminocyclopentanecarboxamide 
• 311341-94-3 ethyl cis-2-isothiocyanato-1-cyclopentanecarboxylate 
• 311341-94-3 ethyl trans-2-isothiocyanato-1-cyclopentanecarboxylate 
• 1609100-30-2 trans-ethyl 2-aminocyclopentanecarboxylate 
• 245115-20-2 ethyl (R,R)-tert-butoxycarbonyl-2-aminocyclopentanecarboxylate 
• 197904-11-3 (1R,2S)-2-aminocyclopentanecarboxylic acid ethyl ester 
• 57043-00-2 (1RS,2SR)-cispentacin 
• 128052-92-6 (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid hydrochloride 
• 245115-25-7 (1R,2R)-2-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylic acid 
• 1422429-03-5 tert-butyl ((1S,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)(ethyl)carbamate 
• 1422429-02-4 2-(4-bromophenyl)-2-oxoethyl (1S,2S)-2-((tert-butoxycarbonyl)(ethyl)amino)cyclopentanecarboxylate 

Relevant academic research and scientific papers

Approach to highly enantiopure β-amino acid esters by using lipase catalysis in organic media

Ethyl esters of ten alicyclic β-aminocarboxylic acids were resolved by lipase catalysis in organic solvents. The resolution was based on acylation of the amino group at the R-stereogenic centre with various 2,2,2- trifluoroethyl esters. An increase in the hydrophobic nature of the acyl donor enhanced the enantioselectivity and reactivity in the case of lipase SP 526 from Candida antarctica, while the opposite effect was observed with lipase PS from Pseudomonas cepacia. An unexceptional enantioselectivity enhancement was observed when 2,2,2-trifluoroethyl chloroacetate was used in the case of lipase PS catalysis.

SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF

Compounds of formula (I), processes for their production and their use as pharmaceuticals.

Diastereoselective Photoredox-Catalyzed [3 + 2] Cycloadditions of N-Sulfonyl Cyclopropylamines with Electron-Deficient Olefins

A highly diastereoselective, visible-light-induced [3 + 2] cycloaddition between N-sulfonyl cyclopropylamines and electron-deficient olefins is reported. The reactions proceed via the oxidation of a sulfonamide aza-anion by an organic photocatalyst to generate a nitrogen-centered radical. Strain-induced ring opening and intermolecular addition to the olefin generate an intermediate carbon-centered radical that is reduced to an anion prior to 5-exo cyclization. This enables a highly diastereoselective construction of trans-cyclopentanes possessing synthetically useful functional groups.

Dirhodium(II)-catalyzed [3 + 2] cycloaddition of N-arylaminocyclopropane with alkyne derivatives

Dirhodium(II) complex-catalyzed [3 + 2] reactions between N-arylaminocyclopropanes and alkyne derivatives are described. The cycloaddition products proved to be versatile synthetic intermediates. trans-Cyclic β-amino acids and derivatives thereof can be c

Dirhodium(II)-Catalyzed (3 + 2) Cycloaddition of the N-Arylaminocyclopropane with Alkene Derivatives

Several (3 + 2) cycloaddition reactions catalyzed by dirhodium(II) complexes between N-arylaminocyclopropane and alkenes derivative have been developed. Preliminary mechanism studies suggest that dirhodium(II) complexes may decrease the bond-dissociation

Synthesis of oxazolidin-2-ones and imidazolidin-2-ones directly from 1,3-diols or 3-amino alcohols using iodobenzene dichloride and sodium azide

A general and efficient method for the synthesis of oxazolidin-2-ones and imidazolidin-2-ones directly from 1,3-diols and 3-amino alcohols has been developed using the same reagent combination of iodobenzene dichloride (PhICl2) and sodium azide (NaN3).

Expanding dynamic kinetic protocols: Transaminase-catalyzed synthesis of α-substituted β-amino ester derivatives

Several α-alkylated β-amino esters have been obtained via DKR processes employing a kit of transaminases and isopropylamine as an amino donor in aqueous medium under mild conditions. Thus, while acyclic α-alkyl-β-keto esters afforded excellent conversions and enantioselectivities, although usually low diastereoselectivities, using more constrained cyclic β-keto esters high to excellent inductions were obtained.

AMINO QUINOLINE DERIVATIVES INHIBITORS OF HCV

A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are defined herein, and methods of treating HCV infection in a patient are disclosed.

Intramolecular ester enolate-imine cyclization reactions for the asymmetric synthesis of polycyclic β-lactams and cyclic β-amino acid derivatives

Enolates of chiral N-(α-methyl-p-methoxybenzyl)-ω-imino-esters undergo intramolecular cyclization reactions to afford (syn)-aza-anions of β-amino esters in high dr that cyclize to afford N-(α-methyl-p- methoxybenzyl)-β-lactams that can be readily deprotec

Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives

Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a γ-secretase enzyme; or (ii) the production of β-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R1, and R2 are described herein.